Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction
A pooled analysis of 10 primary prevention trials
Kumaraswamy Nanthakumar, MD*,*,
Andrew E. Epstein, MD ,
G. Neal Kay, MD,
Vance J. Plumb, MD and
Douglas S. Lee, MD
* Division of Cardiology, University Health Network
Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada
University of Alabama at Birmingham, Birmingham, Alabama
View larger version (18K):
[in a new window]
|
Figure 1 Death from all causes in all available primary prevention trials. Death from all causes in the 10 prophylactic implantable cardioverter-defibrillator (ICD) trials, pooled in a random effects model. For each randomized trial, the number of deaths (n) and the number assigned (N) are shown. The rectangles represent the point estimates of the relative risk (RR) for individual studies, and the 95% confidence intervals (CIs) are shown as bars. The overall pooled RR is 0.75, which significantly favors treatment with the defibrillator (p = 0.003). The horizontal tips of the black diamond represent the 95% CI, and the midpoint of the diamond represents the point estimate of the RR. See the Abbreviations box for trial acronyms.
|
|
View larger version (18K):
[in a new window]
|
Figure 2 Death from all causes in nonselective primary prevention trials. Death from all causes in seven trials (excluding CABG-Patch, DINAMIT, and MUSTT) pooled in a random effects model. For each randomized trial, the number of deaths (n) and the number assigned (N) are shown. The rectangles represent the point estimates of the RR for individual studies, and the 95% CIs are shown as bars. The overall pooled RR is 0.74, which significantly favors treatment with the defibrillator (p = 0.00001). The horizontal tips of the black diamond represent the 95% CI, and the midpoint of the diamond represents the point estimate of the RR. See the Abbreviations box for trial acronyms.
|
|
|
